^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SMARCA4 mutation

    i
    Other names: SMARCA4, SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 4, Mitotic Growth And Transcription Activator, ATP-Dependent Helicase SMARCA4, Global Transcription Activator Homologous Sequence, Transcription Activator BRG1, Sucrose Nonfermenting-Like 4, BRG1-Associated Factor 190A, Protein Brahma Homolog 1, BRM/SWI2-Related Gene 1, Homeotic Gene Regulator, Brahma Protein-Like 1, Nuclear Protein GRB1, Protein BRG-1, SNF2-Like 4, SNF2-Beta, BAF190A, SNF2L4, BRG1,BAF190, SNF2LB, HSNF2b, MRD16, RTPS2, SNF2B, CSS4, SNF2, SWI2
    Entrez ID:
    6597
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    9ms
    Featured today by @MSKLibrary: #SMARCA4 Mutations in #Carcinomas of the Esophagus, #Esophagogastric Junction, and Stomach: https://t.co/SRdw4D48zS @alexanderjneil @JamesClearyMD @feidng (@MSKLibrary)
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    SMARCA4 mutation
    10ms
    Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC 💥KEAP1, SMARCA4 and CDKN2A mutations lead to shorter survival in lung cancer patients treated with KRAS-G12C inhibitors (@mvnegrao et al.) @CD_AACR @MDAndersonNews https://t.co/Vh2FY3pluD https://t.co/EvmUncUHrN (@dr_yakupergun)
    Clinical • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • KEAP1 (Kelch Like ECH Associated Protein 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    KRAS mutation • KEAP1 mutation • CDKN2A mutation • SMARCA4 mutation
    1year
    Fantastic real-world collaboration led by @FSkoulidis: KEAP1, SMARCA4, and CDKN2A mutations contribute to roughly 50% of early progression in KRAS G12C targeted treated #NSCLC. TP53 and STK11 comutations without impact. Happy to be on board. #LCSM @KRASKickers (@trnsltnl)
    Clinical • Real-world evidence • Real-world
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • KEAP1 (Kelch Like ECH Associated Protein 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    TP53 mutation • KRAS G12C • STK11 mutation • KEAP1 mutation • CDKN2A mutation • KRAS G12 • SMARCA4 mutation
    over1year
    Preclinical study from @ArvinasInc in @NatureComms Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers https://t.co/vqZQEC1QN0 SMARCA4 (BRG1) is inactivated in many cancers such as #LungCancer, creating a synthetic essentiality on SMARCA2. (@Aiims1742)
    Preclinical
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
    |
    SMARCA4 mutation
    2years
    Wonder how many UK centres do BRG IHC in #NSCLC or report SMARCA4 mutations on NGS. Few, I’d have thought. Am fortunate to work with a path lab and GLH that does (@DrSanjayPopat)
    Next-generation sequencing
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    SMARCA4 mutation
    over3years
    The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer - SMARCA4 co-occur with KEAP1, STK11, and KRAS mutations. SMARCA4-mutant lung cancers may be more sensitive to immunotherapy. https://t.co/kfwMRtYqJn (@AndresFCardonaZ)
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    KRAS mutation • STK11 mutation • KEAP1 mutation • KRAS mutation + STK11 mutation • SMARCA4 mutation
    almost4years
    SMARCA4 (BRG1) LoF mutation is extremely common in small cell carcinoma of ovary, hypercalcemic type, so might be associated with small-cell biology in some cellular contexts. But it is not frequently mutated in EGFR-mutant lung adenos. (@jakelee0711)
    EGFR (Epidermal growth factor receptor) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    EGFR mutation • SMARCA4 mutation
    almost4years
    Our poster at #ASCO20: Glad to share our work: Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC). https://t.co/h4LJRenxsD Thanks again to @DrMarkAwad for your dedicated mentorship. (@alessi_joao)
    Clinical
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    SMARCA4 mutation